Abstract
Looking from the point of risk of development of cancer are most antidiabetic drugs either neutral or lead to mild increase of the risk. Metformin is the only antidiabetic drug, which in retrospective studies decreased the risk of malignant diseases (OR 0,54 - 0,70).
In the patients treated with metformin were observed also better results of antitumor treatment. Most studies described also lower risk of pancreatic cancer in diabetic patients treated with metformin.
There is a description of patients, treated with metformin from the beginning of pancreatic cancer with prognosis of longer survival compared with those, who were not treated with insulin. On contrary, this is not true, when metformin was started in developer stage of pancreatic cancer.
The article gives the survey of contemporary knowledge in this field.